Akero Therapeutics Inc (NASDAQ: AKRO) kicked off on Monday, up 0.18% from the previous trading day, before settling in for the closing price of $54.55. Over the past 52 weeks, AKRO has traded in a range of $21.34-$58.40.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -5.28%. While this was happening, its average annual earnings per share was recorded -1.75%. With a float of $72.84 million, this company’s outstanding shares have now reached $80.15 million.
Akero Therapeutics Inc (AKRO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 11.51%, while institutional ownership is 103.53%. The most recent insider transaction that took place on Oct 10 ’25, was worth 1,619,340. In this transaction President and CEO of this company sold 30,000 shares at a rate of $53.98, taking the stock ownership to the 526,114 shares. Before that another transaction happened on Oct 07 ’25, when Company’s Chief Scientific Officer sold 12,500 for $46.08, making the entire transaction worth $576,001. This insider now owns 166,571 shares in total.
Akero Therapeutics Inc (AKRO) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.99 earnings per share (EPS), higher than consensus estimate (set at -1.12) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.39% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Take a look at Akero Therapeutics Inc’s (AKRO) current performance indicators. Last quarter, stock had a quick ratio of 15.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -4.31 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Compared to the last year’s volume of 1.7 million, its volume of 5.55 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 71.44%.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 98.32%, which indicates a significant increase from 71.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.17 in the past 14 days, which was lower than the 1.16 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.92, while its 200-day Moving Average is $48.17. Nevertheless, the first resistance level for the watch stands at $54.86 in the near term. At $55.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $55.32. If the price goes on to break the first support level at $54.40, it is likely to go to the next support level at $54.16. Now, if the price goes above the second support level, the third support stands at $53.95.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
The company with the Market Capitalisation of 4.50 billion has total of 82,324K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -252,060 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -81,570 K.
